Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control

Georgios Ponirakis1,2, Muhammad A Abdul-Ghani3,4, Amin Jayyousi3, Mahmoud A Zirie3, Salma Al-Mohannadi1, Hamad Almuhannadi1, Ioannis N Petropoulos1, Adnan Khan1, Hoda Gad1, Osama Migahid3,4, Ayman Megahed3, Murtaza Qazi1, Fatema AlMarri1, Fatima Al-Khayat1, Ziyad Mahfoud1, Ralph DeFronzo4, Rayaz A Malik1,2,3,5*

1Weill Cornell Medicine in Qatar, Qatar Foundation, Education City, Doha, Qatar, 2Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK, 3National Diabetes Center, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar, 4Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas, USA, and 5Institute of Cardiovascular Science, University of Manchester, Manchester, UK

Keywords
Corneal confocal microscopy, Diabetic peripheral neuropathy, Insulin resistance

*Correspondence
Rayaz A Malik
Tel.: +974-4492-8256
Fax: +974-4492-8422
E-mail address: ram2045@qatar-med.cornell.edu

J Diabetes Investig 2021
doi: 10.1111/jdi.13582
Clinical Trial Registry
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM NCT02887625

INTRODUCTION
Diabetic peripheral neuropathy (DPN) occurs in approximately 50% of patients with diabetes, and is associated with neuropathic pain, erectile dysfunction and foot ulcers1. Currently there are no Food and Drug Administration approved treatments for DPN. Intensive glycemic control can delay DPN progression in type 1 diabetes2, but has a limited effect in type 2 diabetes3-6.

Insulin resistance (IR) is characterized by decreased responsiveness of the liver fat and muscle to circulating insulin7. IR is an important risk factor for type 2 diabetes8 and atherosclerosis9, and is associated with hypertension10, obesity11 and dyslipidemia12, many of the risk factors for DPN13. Neurons also show IR14, and it might attenuate the neurotrophic effect of insulin15. IR has been associated with DPN in individuals with type 2 diabetes16,17 and type 1 diabetes13. Furthermore, in the BARI-2D study, the incidence of DPN was lower in patients receiving insulin-sensitizing treatment compared with insulin providing treatment over a 4-year period, even after adjusting for the change in glycated hemoglobin (HbA1c)5.

Previously, we have reported that both exenatide plus pioglitazone or basal–bolus insulin improve corneal nerve branch
density and length, independent of change in HbA1c, bodyweight and lipid profile\textsuperscript{19}. However, after simultaneous pancreas and kidney transplantation in patients with type 1 diabetes, corneal nerve fiber density increased significantly at 6 months followed by an increase in corneal nerve fiber length and corneal nerve branch density\textsuperscript{19,20}. Treatment with the erythropoietic peptide, cibinetide, showed a significant increase in corneal nerve fiber density in patients with type 2 diabetes\textsuperscript{21}, and an increase in corneal nerve fiber area in patients with sarcoidosis and small fiber neuropathy\textsuperscript{22}. A detailed analysis of the change in different corneal nerve parameters showed that an initial increase in the corneal nerve branch density, length and area was indicative of repair to the terminal parts of the basal plexus followed by an increase in corneal nerve fiber density, indicative of more proximal nerve repair\textsuperscript{23}. The objective of the present study was to investigate whether the presence of IR affects corneal nerve regeneration in individuals with type 2 diabetes undergoing intensive glycemic control with exenatide and pioglitazone or basal–bolus insulin over a 12-month period.

**MATERIALS AND METHODS**

This was an exploratory substudy of an open-label, randomized controlled trial (clinicaltrials.gov ID: NCT02887625)\textsuperscript{24} that examined the efficacy of exenatide and pioglitazone versus basal–bolus insulin in patients with poorly controlled type 2 diabetes. This substudy has not been registered in a public clinical trial database. Participants were enrolled from the National Diabetes Center in Doha, Qatar, at baseline and 1-year follow up from October 2016 to November 2018. This study received ethical approval from the Hamad Medical Corporation institutional review board (IRB approval number 13-00076) on 9 May 2016. All subjects consented to participate in the study. The study followed the tenets of the declaration of Helsinki.

**Inclusion and exclusion criteria**

Individuals aged 18–75 years and with HbA1c >7.5% (>58 mmol/mol) on near maximum dose of metformin (>1,500 mg/day) and sulfonylurea (>4 mg glimepiride or >60 mg gliclazide), normal liver and kidney function, electrocardiogram, and stable bodyweight (±1 kg) in the past year were recruited.

Exclusion criteria are described in detail in our previous report\textsuperscript{18}, but included any cause of neuropathy apart from diabetes, corneal dystrophies, corneal surgery or trauma in the past year, antidiabetic treatment other than metformin and sulfonylureas, diabetic proliferative retinopathy, and abnormally high albumin excretion.

**Interventions**

Participants were randomized to exenatide and pioglitazone or glargine and aspart treatment to achieve and maintain an HbA1c <7.0% (<53 mmol/mol)\textsuperscript{24}. There was no limit on the upper value of HbA1c for enrolment. Participants randomized to combination treatment were started on weekly subcutaneous extended release exenatide (2 mg/week Bydureon) and pioglitazone (30 mg/day). Participants receiving insulin were started on glargine before breakfast. The Treat-to-Target Trial (4T) algorithm was used to calculate the starting glargine dose, and the dose was adjusted weekly to achieve a fasting plasma glucose of <6.11 mmol/L. After the fasting plasma glucose goal was achieved, if the HbA1c was >53 mmol/mol (>7.0%), 4–6 units of insulin aspart was started before each meal, and the dose was adjusted to achieve a post-prandial plasma glucose concentration of <7.78 mmol/L, 2 h after meals. Patients were seen monthly during the first 4 months or as required, based on the results of the plasma glucose concentration, and bimonthly thereafter.

**Demographic and metabolic measures**

Age, sex, diabetes duration, body weight, body mass index (BMI), blood pressure, HbA1c, total cholesterol, triglyceride, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) were recorded from the electronic health record.

**Insulin secretion and resistance**

The oral glucose tolerance test was administered in the morning after an overnight fast. Blood samples were collected at −30, −15, 0, 30, 60, 90 and 120 min through a small polyethylene catheter inserted into an antecubital vein to measure plasma glucose and insulin concentrations. Plasma glucose and insulin concentration were measured by the glucose oxidase reaction (Glucose Oxidase Analyzer, Fullerton, CA, USA) and radioimmunoassay (Coat A Coat; Diagnostic Products, Los Angeles, CA, USA), respectively. The insulinogenic index was calculated by the incremental area under the curve of insulin divided by the incremental area under the curve of glucose during the 0- to 120-min (total) time period of the oral glucose tolerance test. Homeostasis model assessment of insulin resistance (HOMA-IR), which reflects hepatic IR\textsuperscript{25}, was used as a surrogate measure of IR\textsuperscript{26,27}. There is considerable variability in the threshold levels that define IR and it does not exclusively reflect insulin sensitivity in patients with type 2 diabetes. However, in two large population-based cohorts, the upper 95th percentiles of HOMA-IR were 1.9 and 2.0\textsuperscript{28}. Therefore, in the current study, participants were categorized as having IR if the HOMA-IR was ≥1.9.

**Neuropathy assessment**

Corneal confocal microscopy (CCM) was undertaken using the HRT-III-RCM device (Heidelberg Engineering GmbH, Heidelberg, Germany), as described previously\textsuperscript{29}. Corneal nerve fiber density (CNFD; fibers/mm\textsuperscript{2}), length (CNFL) (mm/mm\textsuperscript{2}) and branch density (CNBD; branches/mm\textsuperscript{2}) were quantified using CCMetrics\textsuperscript{30}.

**Statistical analysis**

This was an exploratory study, no power calculation was determined, and the results were not adjusted for multiple
comparisons. Participants were randomly assigned to either treatment. Variables between baseline and 1-year follow up were compared using a paired t-test. Changes in clinical, metabolic and CCM measures from baseline to 1-year follow up between participants were compared using an unpaired t-test.

Univariate linear regression analysis was carried out with the corneal nerve measures at baseline and change in the corneal nerve measures as the dependent variables, and HOMA-IR, insulin secretion, blood pressure, bodyweight, BMI, HbA1c, cholesterol, triglyceride, HDL and LDL as independent variables. All significant variables were included in the multiple linear regression analysis. The regression coefficient and corresponding 95% confidence interval are presented. All analyses were calculated using IBM SPSS v. 26 (SPSS Inc., Armonk, NY, USA). A two-tailed P-value ≤0.05 was considered significant.

RESULTS
Baseline and 1-year follow-up clinical and metabolic characteristics
The clinical and metabolic characteristics at baseline and 1-year follow up are summarized in Table 1. The study cohort was comprised of 15 (40%) women and 23 (60%) men aged 50.2 ± 8.5 years, with type 2 diabetes for 10.2 ± 5.2 years. The mean fasting plasma glucose at baseline was 243.5 ± 54.4 mg/dL. There was a significant reduction in HbA1c (10.7% [93 mmol/mol] vs 7.9% [62 mmol/mol], P < 0.0001), diastolic blood pressure (DBP; mmHg) (79.8 vs 73.5, P < 0.0001), total cholesterol (mmol/L; 5.0 vs 4.5, P < 0.01) and LDL (mmol/L; 2.9 vs 2.6, P = 0.05), but no change in systolic blood pressure (SBP; mmHg) (128.8 vs 127.1, P = 0.58), BMI (kg/m²; 31.6 vs 32.0, P = 0.19), triglycerides (mmol/L; 1.9 vs 1.8, P = 0.49) and HDL (mmol/L; 1.2 vs 1.1, P = 0.28). The mean body weight increased significantly (kg; 86.5 to 91.5, P < 0.0001).

There was a significant increase in CNBD (branches/mm²; 67.8 vs 87.5, P < 0.01) and CNFL (mm/mm²; 19.2 vs 21.0, P < 0.05), and a non-significant increase in CNFD (fibers/mm²; 27.6 vs 29.3, P = 0.26).

Association of IR with clinical characteristics and corneal nerve fiber measures
Of the 38 individuals studied, 25 (65.8%) had HOMA-IR ≥1.9 and 13 (34.2%) had HOMA-IR <1.9. Comparison of the plasma glucose and insulin concentrations, and index of insulin secretion and resistance, and the change in clinical characteristics and corneal nerve fiber measures between those with HOMA-IR <1.9 and ≥1.9 are summarized in Table 2. Participants with IR (HOMA-IR ≥1.9) had a significantly lower mean age (45.1 ± 8.4 vs 54.4 ± 7.2, P < 0.05), but comparable duration of diabetes (11.2 ± 5.3 vs 9.6 ± 5.2, P = 0.40) and proportion of women (46.2% vs 36.0%, P = 0.54) compared with those without IR. In both groups, HbA1c decreased (P < 0.001) and body weight increased (P < 0.001), with comparable changes in HbA1c (−2.5% [−28 mmol/mol] vs −3.0% [−32.6 mmol/mol], P = 0.49) and body weight (kg; 6.6 vs 4.2, P = 0.19). Participants with HOMA-IR ≥1.9 showed a significantly greater decrease in DBP (P ≤ 0.01) and total cholesterol (P ≤ 0.01), but the change in DBP (mmHg; −6.8 vs −5.9, P = 0.81) and total cholesterol (mmol/L; −0.5 vs −0.5, P = 0.97) was comparable between both interventions. The change in triglycerides (mmol/L; −0.1 vs −0.2, P = 0.79), HDL (mmol/L; −0.1 vs −0.1, P = 0.78), LDL (mmol/L; −0.3 vs −0.4, P = 0.88), SBP (mmHg; 0.8 vs −3.1, P = 0.53) and BMI (kg/m²; −0.1 vs 0.3, P = 0.61) was comparable between patients with and without IR.

Participants with HOMA-IR <1.9 showed a significant increase in CNFD (P ≤ 0.01), CNBD (P ≤ 0.01) and CNFL (P ≤ 0.01), whereas participants with IR ≥1.9 showed no change (Figure 1). There was a significant difference in the change in CNFD (fibers/mm²; 7.5 vs −1.3, P ≤ 0.01) and CNFL (mm/mm²; 47.0 vs 0.3, P < 0.05), but not in CNBD (branches/mm²; 33.7 vs 12.4, P = 0.16) between patients with and without IR.

Association of insulin secretion, HOMA-IR and clinical characteristics with corneal nerve fiber measures
Linear regression analysis showed a negative association between baseline HOMA-IR as a continuous variable with change (Δ) in CNFD (P < 0.05), but no association with ΔCNBD (P = 0.66) or ΔCNFL (P = 0.75; Table 3). HOMA-IR ranged from 0.2 – 9.1 and for every 1-unit increase, the CNFD decreased by 1.38 fibers/mm² after adjusting for change in bodyweight. There was no association between baseline
Table 2 | Comparison of demographic and clinical characteristics at baseline and change over a 1-year period between participants with type 2 diabetes with and without insulin resistance

|                      | HOMA-IR <1.9 (n = 13) | HOMA-IR ≥1.9 (n = 25) | P-value |
|----------------------|-----------------------|-----------------------|---------|
| Age (years)          | 54.4 ± 7.2            | 45.1 ± 8.4            | <0.05   |
| Sex (female), n (%)  | 6 (46.2)              | 9 (36.0)              | 0.54    |
| Duration of diabetes (years) | 11.2 ± 5.3           | 9.6 ± 5.2             | 0.40    |
| Fasting glucose (mg/dL) | 227.2 ± 54.7        | 257.5 ± 52.6          | 0.11    |
| 2-h glucose (mg/dL)  | 397.9 ± 46.0          | 416.7 ± 69.9          | 0.31    |
| Fasting insulin (µU/mL) | 1.8 ± 1.2            | 6.7 ± 2.6             | <0.0001 |
| 2-h insulin (µU/mL)  | 5.9 ± 7.2             | 104 ± 5.3             | 0.06    |
| Insulinogenic index (mU/L/mg/dL) | 2.7 ± 3.5       | 3.2 ± 3.2             | 0.66    |
| HOMA-IR              | 1.0 ± 0.6             | 4.2 ± 1.8             | <0.0001 |
| Matsuda insulin sensitivity index | 24.9 ± 25.6     | 42 ± 1.4              | 0.01    |
| ΔHbA1c (mmol/mol)    | –27.8 ± 193†††       | –326 ± 205†††         | 0.49    |
| ΔHbA1c (%)           | –2.5 ± 18†††          | –3.0 ± 1.9†††         | 0.49    |
| ΔTotal cholesterol (mmol/L) | –0.5 ± 1.1          | –0.5 ± 1.1†          | 0.97    |
| ΔTriglyceride (mmol/L) | –0.1 ± 0.8           | –0.2 ± 1.3            | 0.79    |
| ΔHDL (mmol/L)        | –0.1 ± 0.3            | –0.1 ± 0.4            | 0.78    |
| ΔLDL, mmol/L         | –0.3 ± 0.9            | –0.4 ± 1.0            | 0.88    |
| ΔSystolic BP (mmHg)  | 0.8 ± 17.6            | –3.1 ± 18.4           | 0.53    |
| ΔDiastolic BP (mmHg) | –6.8 ± 11.9           | –5.9 ± 8.3†          | 0.81    |
| ΔBodyweight (kg)     | 6.6 ± 5.2††          | 4.2 ± 5.1†††         | 0.19    |
| ΔBMI (kg/m²)         | –0.1 ± 2.1            | 0.3 ± 1.4             | 0.61    |
| ΔCNFD (fibers/mm²)   | 7.5 ± 9.6†          | –13 ± 7.6             | <0.01   |
| ΔCNBD (branches/mm²) | 33.7 ± 41.8‡         | 124 ± 44.5            | 0.16    |
| ΔCNFL (mm/mm²)       | 4.7 ± 5.0†          | 0.3 ± 4.9             | <0.05   |

Numerical variables and frequency distribution for categorical variables are summarized as the mean ± standard deviation and n (%), and were compared between participants with type 2 diabetes with homeostasis model assessment of insulin resistance (HOMA-IR) <1.9 and ≥1.9 using unpaired t-test and χ²-test, respectively. Changes between baseline and 1-year follow up were compared using paired t-test: †P ≤ 0.05, ††P ≤ 0.01, †††P ≤ 0.001. BMI, body mass index; BP, blood pressure; CNBD, corneal nerve branch density; CNFD, corneal nerve fiber density; CNFL, corneal nerve fiber length; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

HOMA-IR and baseline CNFD (P = 0.17), CNBD (P = 0.85) or CNFL (P = 0.82), and between baseline insulin secretion and baseline CNFD (P = 0.80), CNBD (P = 0.82), CNFL (P = 0.89) and ΔCNFD (P = 0.43), ΔCNBD (P = 0.77) or ΔCNFL (P = 0.65). There was no association between type of treatment and ΔCNFD (P = 0.13), ΔCNBD (P = 0.35) or ΔCNFL (P = 0.30).

The change in CCM measures was not associated with age (P = 0.14–0.63), duration of diabetes (P = 0.11–0.23), ΔSBP (P = 0.15–0.95), ΔDBP (P = 0.57–0.79), ΔHbA1c (P = 0.37–0.83), Δtriglyceride (P = 0.12–0.61) or ΔLDL (P = 0.47–0.80). There was a negative association between Δbodyweight and ΔCNFD (P < 0.01), but not with ΔCNBD (P = 0.53) or ΔCNFL (P = 0.77), and between Δtotal cholesterol and ΔCNBD (P < 0.05), but not with ΔCNFD (P = 0.36) or ΔCNFL (P = 0.81).

Effect of treatment on neuropathy progression with HOMA-IR <1.9 and ≥1.9

Of 38 participants, 26 (68%) received pioglitazone and exenatide, and 12 (32%) received basal–bolus insulin. Of 25 participants with HOMA-IR ≥1.9, 18 (72%) received pioglitazone and exenatide, and seven (28%) received insulin. There was no significant difference in CNFD (fibers/mm²; 3.2 vs –3.0, P = 0.13), CNBD (branches/mm²; 36.8 vs 2.9, P = 0.12) and CNFL (mm/mm²; 2.1 vs –0.4, P = 0.15) between participants receiving insulin or combination treatment.

Of the 13 participants with HOMA-IR <1.9, eight (61.5%) received pioglitazone and exenatide, and five (38.5%) received insulin. The change in CNFD (fibers/mm²; 5.8 vs 8.5, P = 0.67), CNBD (branches/mm²; 36.6 vs 31.9, P = 0.84) and CNFL (mm/mm²; 4.4 vs 4.8, P = 0.86) was comparable between participants receiving combination compared to insulin treatment.

DISCUSSION

The present study found that the presence of IR might impact on the capacity for corneal nerve regeneration after an improvement in glycemic control, irrespective of treatment with pioglitazone and exenatide or basal–bolus insulin. Participants with IR showed no change in corneal nerve measures, whereas participants without IR showed a significant increase in corneal nerve fiber density.
nerve fiber density, branch density and length indicative of both proximal and distal nerve regeneration. Baseline insulin secretion was not associated with change in corneal nerve measures.

Consistent with our recent study\(^{18}\), the improvement in HbA1c and other risk factors associated with IR including diastolic blood pressure, total cholesterol and LDL were not associated

| Figure 1 | Change in corneal nerve fiber density, branch density and fiber length in participants with (a–c) homeostasis model assessment of insulin resistance (HOMA-IR) <1.9 and (d–f) HOMA-IR ≥1.9 between baseline and 1-year follow up. CNBD, corneal nerve branch density; CNFD, corneal nerve fiber density; CNFL, Corneal nerve fiber length; FU, follow up. |

| Table 3 | Linear regression analyses to determine the association of corneal nerve fiber measures with insulin resistance as a continuous variable |

| | Beta coefficient | 95% Confidence interval | P-value |
|---|---|---|---|
| Baseline CNFD (fibers/mm\(^2\)) | 0.94 | -0.41, 2.29 | 0.17 |
| HOMA-IR | 0.94 | -0.41, 2.29 | 0.17 |
| Change in CNFD (fibers/mm\(^2\)) | -1.38 | -2.64, -0.11 | <0.05 |
| HOMA-IR | -1.38 | -2.64, -0.11 | <0.05 |
| Change bodyweight (kg) | -0.82 | -1.36, -0.28 | <0.01 |
| Baseline CNBD (branches/mm\(^2\)) | 0.53 | -5.11, 6.18 | 0.85 |
| HOMA-IR | 0.53 | -5.11, 6.18 | 0.85 |
| Change in CNBD (branches/mm\(^2\)) | 2.55 | -3.65, 8.76 | 0.41 |
| HOMA-IR | 2.55 | -3.65, 8.76 | 0.41 |
| Change in total cholesterol | -16.19 | -29.27, -3.11 | <0.05 |
| Baseline CNFL (mm/mm\(^2\)) | 0.10 | -0.77, 0.96 | 0.82 |
| HOMA-IR | 0.10 | -0.77, 0.96 | 0.82 |
| Change in CNFL (mm/mm\(^2\)) | -0.13 | -0.94, 0.68 | 0.75 |
| HOMA-IR | -0.13 | -0.94, 0.68 | 0.75 |

All the variables considered in the fitted model had P < 0.05. CNBD, corneal nerve branch density; CNFD, corneal nerve fiber density; CNFL, corneal nerve fiber length; HOMA-IR, homeostasis model assessment of insulin resistance. Shades denote the content of each column.
with change in corneal nerve measures, whereas weight gain in both treatment groups was inversely associated with the change in corneal nerve fiber density.

There is a considerable literature linking IR and insulin action to neuronal integrity in the brain of patients with Alzheimer’s disease, and the effect of pioglitazone and glucagon-like peptide-1 therapy on dementia is currently being evaluated in ongoing trials. A few studies have investigated the impact of IR on DPN in individuals with type 2 diabetes and type 1 diabetes. A cross-sectional study of 86 individuals with type 2 diabetes in Korea reported a significant association between IR and DPN assessed using a neurological examination and nerve conduction studies. In the current study, we found no association between IR and corneal nerve measures, which might be attributed to differences in BMI, HbA1c and duration of diabetes in our cohort compared with the Korean study. Both obesity and higher HbA1c are associated with reduced corneal nerves and DPN, as well as painful DPN. In relation to the impact of IR on incident DPN, a prospective study showed an association between IR and a reduction in sensory nerve action potential over a period of 6 years. The European Diabetes (EURODIAB) Prospective Complications Study of 1,172 individuals with type 1 diabetes reported that lower estimated glucose disposal rate (higher IR) at baseline was associated with the development of DPN after adjusting for diabetes duration and HbA1c. The current study shows that IR at baseline reduced the impact of improved glycemic control with pioglitazone and exenatide or basal–bolus insulin on small nerve fiber regeneration. Lifestyle interventions through increased physical activity and weight loss reduce IR, and lower the risk for type 2 diabetes in individuals with high IR, reduce the prevalence of cardiovascular risk factors, and improve painful neuropathic symptoms and intraepidermal nerve fiber density in individuals with impaired glucose tolerance.

In individuals with insulin resistance, basal–bolus insulin treatment showed a trend for greater corneal nerve regeneration compared with pioglitazone plus exenatide treatment. This might be attributed to the direct neurotrophic effect of insulin, independent of underlying IR. We have previously reported greater corneal nerve fiber regeneration, and an improvement in vibration perception with insulin treatment. Furthermore, Aizmi et al. showed greater corneal nerve regeneration in patients treated with continuous subcutaneous insulin infusion compared with multiple daily insulin injection despite comparable HbA1c, suggesting that continuous subcutaneous insulin infusion might provide more stable blood glucose control and a direct neurotrophic benefit of continuous insulin on nerves.

The increase in corneal nerve fiber density, length and branch density in patients without insulin resistance indicates both proximal and distal nerve regeneration. Our previous studies after simultaneous pancreas and kidney transplantation in type 1 diabetes patients, and after bariatric surgery in obese patients have also shown an increase in corneal nerve fiber density, length and branch density. Ciguabine showed an increase in corneal nerve fiber density in patients with type 2 diabetes and an increase in corneal nerve fiber area in patients with sarcoidosis. Treatment of patients with type 1 diabetes with Omega-3 resulted in an increase in corneal nerve fiber length and branch density with no change in nerve fiber density. These differences in the extent and type of nerve regeneration highlight the need to take into account underlying patient characteristics when determining outcomes in clinical trials.

A significant study limitation of the present study was the small sample size, and as such, subgroup analysis based on categorization of IR was not powered to adequately assess the response to different treatment arms. The classification of patients into those with and without significant IR based on the HOMA-IR cut-off of 1.9 was useful, but should be interpreted with caution, as it depends on insulin secretion, the insulin assay and HOMA-IR calculation. CCM is an objective biomarker of small nerve fiber degeneration and regeneration, and can predict the development of DPN. However, the current study was not powered to assess whether the presence of insulin resistance can prevent or delay incident DPN. We also acknowledge a lack of blinding for patients and investigators due to weekly injections of exenatide and multiple daily insulin injections. However, the investigator who measured the corneal nerve morphology was masked to the treatment group.

In conclusion, the present study found that patients with type 2 diabetes and IR show blunted small nerve fiber regeneration despite a substantial improvement in glycemic control. Therefore, lifestyle interventions, such as physical activity and weight reduction to improve IR might benefit DPN. Furthermore, IR should be considered as a potential confounder when assessing the benefits of disease-modifying therapies in clinical trials for DPN.

ACKNOWLEDGMENTS
We thank all study participants involved in the study. This work was funded by the Qatar National Research Fund (BMRP-5726113101 and NPRP 5-273-3-079). AstraZeneca supplied exenatide for the study.

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136–154.
2. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–984.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995; 28: 103–117.

4. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010; 376: 419–430.

5. Pop-Busui R, Lu J, Brooks MM, et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. *Diabetes Care* 2013; 36: 3208–3215.

6. Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. *Cochrane Database Syst Rev* 2012; CD007543.

7. Sesti G. Pathophysiology of insulin resistance. *Best Pract Res Clin Endocrinol Metab* 2006; 20: 665–679.

8. Reaven GM. Role of insulin resistance in human disease. *Diabetes* 1988; 1988: 1595–1607.

9. Beverly JK, Budoff MJ. Atherosclerosis: Pathophysiology of diabetic neuropathy. *Clin Endocrinol Metab* 1991; 14: 173–194.

10. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. *N Engl J Med* 1987; 317: 350–357.

11. Kahn BB, Flier JS. Obesity and insulin resistance. *J Clin Invest* 2000; 106: 473–481.

12. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care* 1991; 14: 173–194.

13. Tesfaye S, Chaturvedi N, Eaton SE, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010; 376: 419–430.

14. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010; 376: 419–430.

15. Pop-Busui R, Lu J, Brooks MM, et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. *Diabetes Care* 2013; 36: 3208–3215.

16. Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. *Cochrane Database Syst Rev* 2012; CD007543.

7. Sesti G. Pathophysiology of insulin resistance. *Best Pract Res Clin Endocrinol Metab* 2006; 20: 665–679.

8. Reaven GM. Role of insulin resistance in human disease. *Diabetes* 1988; 1988: 1595–1607.

9. Beverly JK, Budoff MJ. Atherosclerosis: Pathophysiology of diabetic neuropathy. *Clin Endocrinol Metab* 1991; 14: 173–194.

10. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. *N Engl J Med* 1987; 317: 350–357.

11. Kahn BB, Flier JS. Obesity and insulin resistance. *J Clin Invest* 2000; 106: 473–481.

12. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care* 1991; 14: 173–194.

13. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. *N Engl J Med* 2005; 352: 341–350.

14. Kim B, McLean LL, Philip SS, et al. Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. *Endocrinology* 2011; 152: 3638–3647.

15. Guo G, Kan M, Martinez JA, et al. Local insulin and the rapid regrowth of diabetic epidermal axons. *Neurobiol Dis* 2011; 43: 414–421.

16. Lee KO, Nam JS, Ahn CW, et al. Insulin resistance is independently associated with peripheral and autonomic neuropathy in Korean type 2 diabetic patients. *Acta Diabetol* 2012; 49: 97–103.

17. Cho YN, Lee KO, Jeong J, et al. The role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: a 6-year follow-up study. *Yonsei Med J* 2014; 55: 700–708.

18. Poniarkis G, Abdul-Ghani MA, Jayyousi A, et al. Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study. *BMJ Open Diabetes Res Care*. 2020; 8: e001420.

19. Tavakoli M, Mitu-Pretorian M, Petropoulos IN, et al. Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. *Diabetes* 2013; 62: 254–260.

20. Azmi S, Jezierska M, Ferdousi M, et al. Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. *Diabetologia* 2019; 62: 1478–1487.

21. Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoetin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. *Mol Med* 2015; 20: 658–666.

22. Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. *Invest Ophthalmol Vis Sci* 2017; 58: BIO52–BIO60.

23. Brines M, Culver DA, Ferdousi M, et al. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. *Sci Rep* 2018; 8: 4734.

24. Abdul-Ghani M, Migahid O, Megahed A, et al. Combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with poorly controlled type 2 diabetes on sulfonylurea plus metformin: the Qatar study. *Diabetes Care* 2017; 40: 325–331.

25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412–419.

26. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. *Med Clin North Am* 2007; 91: 1063–1077, viii.

27. Antuna-Puente B, Disse E, Rabasa-Lhoret R, et al. How can we measure insulin sensitivity/resistance? *Diabetes Metab* 2011; 37: 179–188.

28. Isokuortti E, Zhou Y, Peltonen M, et al. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. *Diabetologia* 2017; 60: 1873–1882.

29. Petropoulos IN, Alam U, Fadavi H, et al. Corneal nerve loss detected with corneal confocal microscopy is symmetrical and related to the severity of diabetic polyneuropathy. *Diabetes Care* 2013; 36: 3646–3651.

30. Dabbah MA, Graham J, Petropoulos IN, et al. Automatic analysis of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging. *Med Image Anal* 2011; 15: 738–747.

31. Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology* 1990; 1: 43–46.

32. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. *J Clin Invest* 2012; 122: 1316–1338.
33. Galimberti D, Scarpini E. Pioglitazone for the treatment of Alzheimer’s disease. *Expert Opin Investig Drugs* 2017; 26: 97–101.

34. Femminella GD, Frangou E, Love SB, et al. Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study). *Trials* 2020; 21: 660.

35. Ponirakis GAS, Ferdousi M, Petropoulos IN, et al. The impact of bariatric surgery on neuropathic pain and on objective markers of neuropathy. Qatar Foundation Annual Research Conference Proceedings. 2016; 2016(1).

36. Ishibashi F, Okino M, Ishibashi M, et al. Corneal nerve fiber pathology in Japanese type 1 diabetic patients and its correlation with antecedent glycemic control and blood pressure. *J Diabetes Investig* 2012; 3: 191–198.

37. Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. *Diabet Med* 2011; 28: 1261–1267.

38. Ponirakis G, Elhadd T, Chinnaiyan S, et al. Prevalence and management of diabetic neuropathy in secondary care in Qatar. *Diabetes Metab Res Rev* 2020; 36: e3286.

39. Ponirakis G, Elhadd T, Chinnaiyan S, et al. Prevalence and risk factors for painful diabetic neuropathy in secondary healthcare in Qatar. *J Diabetes Investig* 2019; 10: 1558–1564.

40. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001; 344: 1343–1350.

41. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. *Ann Intern Med* 2005; 142: 611–619.

42. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. *Diabetes Care* 2006; 29: 1294–1299.

43. Azmi S, Ferdousi M, Petropoulos IN, et al. Corneal confocal microscopy shows an improvement in small-fiber neuropathy in subjects with type 1 diabetes on continuous subcutaneous insulin infusion compared with multiple daily injection. *Diabetes Care* 2015; 38: e3–4.

44. Zochodne DW. Sensory neurodegeneration in diabetes: beyond glucotoxicity. *Int Rev Neurobiol* 2016; 127: 151–180.

45. Adam S, Azmi S, Ho JH, et al. Improvements in diabetic neuropathy and nephropathy after bariatric surgery: a prospective cohort study. *Obes Surg* 2021; 31: 554–563.

46. Lewis EJH, Lovblom LE, Cisbani G, et al. Baseline omega-3 level is associated with nerve regeneration following 12-months of omega-3 nutrition therapy in patients with type 1 diabetes. *J Diabetes Complications* 2020; 35: 107798.

47. Manley SE, Luzio SD, Stratton IM, et al. Preanalytical, analytical, and computational factors affect homeostasis model assessment estimates. *Diabetes Care* 2008; 31: 1877–1883.

48. Pritchard N, Edwards K, Russell AW, et al. Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes. *Diabetes Care* 2015; 38: 671–675.

49. Lovblom LE, Halpern EM, Wu T, et al. In vivo corneal confocal microscopy and prediction of future incident neuropathy in type 1 diabetes: a preliminary longitudinal analysis. *Can J Diabetes* 2015; 39: 390–397.

50. Edwards K, Pritchard N, Dehghani C, et al. Corneal confocal microscopy best identifies the development and progression of neuropathy in patients with type 1 diabetes. *J Diabetes Complications* 2017; 31: 1325–1327.